Authors: Jaco Voorham Peter GM Mol Hiddo J Lambers Heerspink Dick de Zeeuw Petra Denig
Publish Date: 2015/03/19
Volume: 10, Issue: 3, Pages: 142-143
Abstract
Monitoring the use of new drugs in practice is important especially when there are safety concerns The novel direct renininhibitor aliskiren was registered in Europe in Aug 2007 as an antihypertensive agent Whether combined use with other blockers of the reninangiotensinsystem ACEi or ARB would offer further benefit in highrisk patients was tested in the ALTITUDE trial starting Oct 2007
Keywords: